Two scientists made huge bets on 'impossible' cancer treatments. They're finally paying off.

Moderna and Merck's experimental melanoma vaccine, combined with Keytruda, reduced recurrence or death risk by 42% in a Phase 3 trial. Despite positive results, Moderna's shares fell 18%, likely due to high investor expectations. The vaccine is personalized using mRNA technology, targeting unique tumor mutations. Trial data showed 82.2% of patients treated with the vaccine and Keytruda were alive without recurrence after two years, compared to 70% with Keytruda alone.

Moderna and Merck reported late-stage trial results showing their personalized mRNA melanoma vaccine, intismeran, reduced relapse risk by 42% when combined with Keytruda. The trial involved 1,137 patients, with 82% of vaccine recipients showing no recurrence after two years, compared to 70% for the placebo group. The companies plan to present the findings at a medical conference and continue long-term studies.

Moderna's cancer vaccine trial showed a 42% reduction in melanoma recurrence risk when combined with immunotherapy, but investors reacted negatively, causing shares to drop 19%. Analysts noted the results fell short of expectations. Merck, the co-developer, faces challenges as Keytruda's patent nears expiration. Experts highlight cost and patient-specific factors in treatment decisions.

Merck and Moderna reported positive results from a cancer vaccine trial. The personalized vaccine, combined with existing immunotherapy, reduced melanoma recurrence by training the immune system to target cancer cells, according to the study.

Moderna (MRNA) shares fell 1% on Friday, following a 17% drop the prior day, as investors reacted to leaked data from a late-stage melanoma vaccine trial. The data, set for official release on Saturday, initially underwhelmed investors. Analysts' price targets vary, with Goldman Sachs at $137, Morgan Stanley at $95, and Citi at $80. The stock has rallied this year on hopes for its cancer treatment pipeline.

Trading volume for Hyperliquid’s MRNA perpetual contract surged to $104 million after Moderna’s cancer-vaccine clinical data was released, with open interest nearly tripling. Volume and open interest later returned to pre-event levels.